Clinical trials
Breast Cancer Screening and Diagnosis clinical trials
Below are recruiting breast cancer screening and diagnosis clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06304857RecruitingPhase 3
Protecting the heart with dapagliflozin during breast cancer treatment
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
Wroclaw, Lower Silesian VoivodeshipAges 18–80 - NCT07262138Recruiting
Active monitoring for older women with early breast cancer
This trial studies whether active monitoring (watchful waiting) can be a safe option instead of immediate surgery or other treatments for women 70 and older who have a small, slow-growing type of breast cancer. If you join, you will not have surgery or other treatments right away, but your cancer will be closely watched.
Pittsburgh, PennsylvaniaAges 70 years+ - NCT06195306RecruitingPhase 2
Low dose tamoxifen and omega-3 for breast cancer prevention
This study tests whether low-dose tamoxifen (a breast cancer prevention drug) or omega-3 supplements can lower breast cancer risk in postmenopausal women who are overweight and have a higher chance of getting the disease. The study lasts about 6 months and involves blood draws and a breast fluid test to see how the treatment affects breast cells.
Kansas City, KansasAges 45–74 - NCT06100263Recruiting
Breast cancer resilience exercise program for Black women
This study tests a personalized exercise program designed to help Black women build strength and resilience after breast cancer treatment. It aims to see if guided exercise can improve physical and emotional well-being.
Ann Arbor, MichiganAges 18 years+ - NCT06467149Recruiting
Comparing Frailty Screenings in Older Breast Cancer Patients
This study compares different ways to check frailty (a measure of how well your body handles stress) in women with breast cancer who are 50 or older. The goal is to find which screening tool best predicts health outcomes during treatment.
ChongqingAges 50 years+ - NCT04020575RecruitingPhase 1
CAR T cells made from your blood for advanced breast cancer
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
Duarte, CaliforniaAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT06995898Recruiting
A new way to screen for cancer
This study tests a new blood test to find cancer early. You will give blood samples and let researchers look at your medical records for one year.
Pleasanton, CaliforniaAges 45–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07520760RecruitingPhase 2
Eribulin Plus Anlotinib for HER2-Negative Breast Cancer
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
GuangzhouAges 18 years+ - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT04626440Recruiting
Testing DNA/RNA tools to study different breast cancer types
This study uses special DNA and RNA testing tools to better understand differences between breast cancer tumors in Taiwanese patients. It may help doctors choose more personalized treatment approaches by learning how tumors vary.
TaipeiAges 20 years+ - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04481763RecruitingPhase 1/Phase 2
Camrelizumab plus radiation for early triple-negative breast cancer
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
Nanchang, JiangxiAges 18–75 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06977893RecruitingPhase 3
Chemo and immunotherapy for HR+ breast cancer before surgery
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
HangzhouAges 18–75 - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT06671262RecruitingPhase 2
Immunotherapy plus radiation before breast cancer surgery
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hangzhou, ZhejiangAges 18–85
Hear when a new Breast Cancer Screening and Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening and diagnosis?
- Yes. Clin2 currently lists 254 recruiting breast cancer screening and diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening and diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening and diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.